Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GTHPD now has nothing left in its bag of tricks to help it stay afloat. The reverse splits are done for good (there's hardly enough stock left to function, the financing is supposed to be done, and now we wait on news of further sales breakthroughs plus the company's attempt to amend its NDA and get it to the new lead reviewer at the FDA ASAP. A tall order!
Going to wait out the RS. Then will die in after if things are looking good
See how long it stays above a buck, my guess is soon we see. $.50
Typical post reverse-split response....down!
NO way.Bounce before RS is imminent.
No reverse splits normally are bad for shareholders. In this case however I do think that we are seeing a major turnaround for this company. I wish I wasn't so busy Friday and would have seen the news to flip and get out...but I didn't and so we shall see what happens come monday-weds.
I'll be keeping it on watch as they have emerged from bankruptcy and should have a lower float with the reverse split
How high can the stock go is my question. I own only 275K shares but seeing how much it dropped on Friday is it really going to outperform? Of course I hope it does but I just don't know. Also are reverse splits usually good for shareholders?
I look forward to running this company as they make the bend, currently I own 5% of the company with how far the shares dropped my shares avg .0025 which is crazy when I first bought they were at 75 cents. I will wait to see what happens.
agreed, But $GTHP is a share producing scam. This company should be shut down and the company executives put in jail with all the fake pr's imo. And they are all fake imo Nobody should be allowed to to a 800-1 reverse split with 150 million shares roughly outstanding. Thats screams blatant scam imo. Sad. I lost $100 trying to catch a quick but i knew Friday afternoon's are bad news when a company is about destroy its shareholders. Criminals imo
Great I hope your right yesterday then I will be able to buy this company and run it!
Knew that how trading was this week that the reverse would happen either today or Monday.
The bounce will be straight down, open will be $1.68 and would guess that by Wednesday next week the pps will drop to $.56 exactly where it was prior this week's trading ($.0007), however don't believe it will stop there my best guess is that soon afterwards we will have a new pps channel at $.10 - $.20
PS, told you so.
google "denied reverse splits and FINRA", it does happen.
not here.
GTHP one for 800 reverse split:
http://otce.finra.org/DLSymbolNameChanges
My guess is next week!
This will run to a new level high very soon .
$GTHP "Elimination of “Toxic” Convertible Securities from its Balance Sheet" This is very positive for the stock.
Big bounce coming.
That means a big bounce is coming.Probably this afternoon.
GTHP = Out of the fry pan & into the fire... 1/800 RS on Monday... http://otce.finra.org/DailyList
Show a link that's not true.
If anyone (accredited investors only) is interested in participating in the secondary, they can obtain a prospectus from Nick Stergis at Ladenburg Thalmann Financial Services Inc. I have no idea how the subscription level is...but i am sure they would welcome more participation.
Saw that the reverse is scheduled for Monday. Let's see how much the company can buy or if it slips back to triple zeros!
Now we know why the run-up began. Secondary must have worked out....
1:800 R/S Monday, per FINRA.
http://otce.finra.org/dailylist
As I stated earlier, the Reverse Split will only happen IF the secondary proceeds. It should happen a few days before the offering is completed. Day traders are having fun with the stock right now...makes me wish I had participated in the volatility. The company does need the stock price as high as they can get it prior to the Reverse Split. Investment banker requirement....
told ya, just some sellers, ask wasn't dropping, it drop somewhat but look how fast it jumped
GTHP (.0039) Time to move those bids up!
yep, ask not dropping, just sellers hitting bid.
Agree, it should go at least and test $0.01- $0.014 highs $GTHP
chart shows .01 break and she's off and running.
Agreed, may be no R/S or it could have been denied by FINRA, go ahead and and google "denied reverse splits and FINRA", it does happen.
No. R/S might not happen at all.
Anybody here know day of RS? TIA
Bids @ $0.004 above closing price @ $0.0038 $GTHP
Yeah right, btw aluminum hats are on sale Saturday, get them now before they sell out!
Everything is leading to about the same losses today that were gained this week, and then Monday we'll see if reverse news comes out.
thanks for the information...
Exactly.... this should have been approved years ago... but big pharma would lose billions if this was approved. Come to your own conclusion
Most people would prefer a non-invasive procedure. The fact that a chinese company got in, opens up a door to serve 2 billion people. A chinese regulatory approval would make GTHP a 15-20 MILLION dollar company, an FDA approval.. would push its cap to 35-55 million. Since it is a non-invasive device, FDA basically would have no reason to deny it, in my view.
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4218
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
Guided Therapeutics, Inc.
Guided Therapeutics, Inc. has developed a platform technology for the early detection of disease that leads to cancer. Based on our patented biophotonic technology, the products use light to detect disease at the cellular level and provide painless and immediate results at the time of the examination.
Testing for cancer today usually involves a taking a tissue sample, like a biopsy, and sending it out to a specialist at a laboratory for results. Patients worry while waiting on test results and in many instances are given the wrong diagnosis – in most cases a false-positive result. A false positive diagnosis means the patient will undergo more testing only to discover later that they are healthy.
Our technology non-invasively scans the suspicious tissue with cool white light providing results, that studies have shown, can detect pre-cancer up to two years earlier than the tissue-sample method and with fewer false-positive results. This means less pain, no time waiting for results and fewer unnecessary treatments.
Our first non-invasive cancer detection product is the LuViva® Advanced Cervical Scan. LuViva is in use in Canada, Latin America, Europe, Asia and Africa and is under premarket application (PMA) review by the U.S. Food and Drug Administration.
LuViva is designed to determine the true likelihood of treatable cervical disease that may lead to cancer in women aged 16 years and over who have been screened for cervical cancer and have an abnormal result. About 80% or more women with an abnormal result at this point in the testing process will eventually be diagnosed as having a false positive result – but after having an unnecessary colposcopy and biopsy. A one-minute scan with LuViva can rule out about 40% of the false-positive cases immediately without the need for colposcopy and biopsy. LuViva has also been shown in clinical trials to identify disease up to two years earlier than colposcopy and biopsy.
LuViva has also shown promise as a potential screening tool in the developing world to be used where the Pap test or HPV test are not widely available. A clinical trial is underway to expand LuViva’s capabilities as a non-invasive cervical cancer screening product.
After breast cancer, cervical cancer is the second most common cancer affecting women’s health. It is a leading cause of cancer deaths in the developing world for women of childbearing age.
Incidence of Cervical Cancer Worldwide:
In the U.S.:
Screening and diagnosis are effective but costly in developed regions of the world. Common screening methods that lead to additional testing are positive for human papillomavirus (HPV) or an abnormal Pap test (cytology).
In developing regions, where screening methods are less commonly available, there is a different story.
“In sub-Saharan Africa, 34.8 new cases of cervical cancer are diagnosed per 100 000 women annually, and 22.5 per 100 000 women die from the disease. These figures compare with 6.6 and 2.5 per 100 000 women, respectively, in North America. The drastic differences can be explained by lack of access to effective screening and to services that facilitate early detection and treatment,” World Health Organization report.
Testing for cervical cancer today in the developed world involves taking a tissue sample – like a Pap test (cytology) for screening or a biopsy for diagnosis and sending the samples to a laboratory where they are read by a medical specialist. Results can take several days or weeks, delaying treatment and creating a time of uncertainty for the patient and her family.
In the developing world it’s a different story. Screening programs may be limited to a portion of the population in the larger cities with almost no screening is the rural areas.
LuViva can improve care in both situations.
In the Developed World:
Up to 80% or more of colposcopies and biopsies for for women who have abnormal Pap tests are found later to be normal or not necessary. If HPV is used for screening those rates could go up.
Unmet Clinical Need for LuViva: A non-invasive “triage” product to determine which patients that screen positive with Pap/HPV need a biopsy (true positives) and which don’t (normal or false positive).
In the Developing World:
Cervical cancer remains a leading cause of cancer death for women of childbearing age due to the lack of laboratory infrastructure.
Unmet Clinical Need for LuViva: A non-invasive “screening” product that provides an immediate result in countries with little Pap/HPV screening.
The platform technology that is LuViva can be applied to other forms or carcinoma. We’ve conducted human testing with the technology on patients at risk for esophageal cancer with promising results. While a great deal more testing and development work needs to be done on that product, we believe that there is a need for our technology in the esophageal market.
Other cancers, in addition to cervical and esophageal, where the technology can be applied:
Our business model is based on sales of a device, in this case the LuViva® Advanced Cervical Scan and a single-use, disposable patient interface called the Cervical Guide. The continuing revenue from the Cervical Guides provides value for our shareholders. The Cervical Guide provides calibration of the LuViva before each test and assures the patient of a cross-contamination free examination.
Read more about our value propositions.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |